The 11th NO-Age/AD conference – a focus on dementia biomarkers, diagnosis, and treatment

16 March 2026 (Monday)
On-line zoom with free registration **here**
Room: Domus Medica, Auditorium L-200
Address: Sognsvannsveien 9, 0372 Oslo, Norway

Organizers:
Evandro F. Fang-Stavem (Oslo, Norway)
Linda Bergersen (UiO, Norway)
Jon Storm-Mathisen (UiO, Norway)
Hilde Nilsen (UiO, Norway)
Asgeir Kobro-Flatmoen (NTNU, Norway)

Poto_EFF

Welcome message by the NO-Age/AD board members

The ageing population is growing rapidly across the Nordic countries and beyond, leading to increased healthcare and socioeconomic challenges. Ageing is the primary risk factor for many diseases, including neurodegenerative diseases such as Alzheimer's disease (AD). Our understanding of the molecular mechanisms underlying brain ageing and neurodegeneration remains limited.

Held in Norway, the NO-Age/AD meeting series bring together leaders in the fields to explore key topics, including molecular mechanisms of ageing and dementia, multi-omics approaches, artificial intelligence applications, neurodegeneration, and translational drug development. Speakers are leaders in these fields around the world! This meeting series also strongly support young researchers by reserving space for short talks and a poster session, ensuring the next generation of scientists to play active roles in advancing the field. By facilitating interdisciplinary discussions and collaborations, we aim to drive innovation towards a future of healthy ageing and improved treatments for age-related diseases.

Organizers:
Evandro F. Fang-Stavem (Oslo, Norway)
Linda Bergersen (UiO, Norway)
Jon Storm-Mathisen (UiO, Norway)
Hilde Nilsen (UiO, Norway)
Asgeir Kobro-Flatmoen (NTNU, Norway)

The 11th NO-Age/AD meeting – a focus on dementia biomarkers, diagnosis, and treatment

16 March 2026, Oslo, Norway

Venue: Domus Medica, Auditorium L-200 (Address: Sognsvannsveien 9, 0372 Oslo), University of Oslo, Norway

Organizers: Evandro F. Fang-Stavem, Linda Bergersen, Jon Storm-Mathisen, Hilde Nilsen (UiO, Norway), Asgeir Kobro-Flatmoen (NTNU, Norway)

On-site and zoom (zoom registration). All welcome, registration free and mandatory

Linda H. Bergersen
UiO, Norway

Jon Storm-Mathisen
UiO, Norway

Hilde Nilsen
UiO, Norway



A. Kobro-Flatmoen
NTNU, Norway
(not attend)

Evandro F. Fang
UiO/Ahus, Norway

Harald Hrubos-Strøm
UiO, Norway



Hua HU
UiO, Norway



Guojun Bu
HKUST, Hong Kong

Xiao-Chun CHEN
Fu-Jian M. U., China

Jin-Tai YU
Fu-Dan U., China

Jia-Wei Xin
Fu-Jian M. U., China

Zao HAN
SMIDF, China

Beatriz Escobar Doncel
Ahus, Norway

Johannes Frank
Ahus, Norway

Anne Brita Knapskog
OUS, Norway

Rune Enger
UiO, Norway

Leiv Otto Watne
Ahus, UiO, Norway

Per Selnes
Ahus, Norway

Fei-Xiong CHENG
Cleveland Clinic, USA



Yong SHEN
USTC, China

Shi Liu
Oxford and Nxera Pharma UK

UiO

NO-Age

NO-AD

The Fang Lab

MitAD

AKERSHUS UNIVERSITETSSYKEHUS

S.M.I.D.F
上海医学创新发展基金会
Shanghai Medical Innovation & Development Foundation

Pictures: designated institutions

One-day event – Monday 16 March 2026

08:00-08:30	08:00-08:10: Opening speech by Prof. Jon Storm-Mathisen (UiO) 08:10-08:20: Opening speech and a short lecture by Prof. Xiao-Chun CHEN (Chair of the China AD Union) 08:20-08:30: Short speech by Zao Han (SMIDF, China)	
PART 1: AD omics and diagnosis		
Chair: Profs. Linda Bergersen and Evandro Fang (UiO, Norway)		
08:30-09:00	Feixiong Cheng (Cleveland Clinic, USA)	The applications of multi-omics in AD mechanistic studies and drug development
09:00-09:30	Johannes Frank (UiO, Norway)	Ferroptosis in ageing and AD
09:30-10:00	Break	
Chair: Prof. Guojun BU (HKUST, Hong Kong)		
10:00-10:30	Yong SHEN (USTC, China)	Novel mechanisms of dementia and related drug development
10:30-11:00	Jin-Tai YU (Fu-Dan U. China)	AD biomarkers and mechanisms – based on the Chinese population (tentative)
11:00-11:30	Per Selnes (Ahus, Norway)	Mitochondria, CSF production, and clearance: why context matters
11:30-12:00	Guojun Bu (HKUST, Hong Kong)	APOE in brain lipid metabolism and Alzheimer's disease (confirmed)
12:00-13:00	Lunch and network	
PART 2: Dementia treatments and related conditions (delirium, sleep)		
Chair: Prof. Hilde Nilsen (UiO, Norway) and Yong SHEN (USTC, China)		
13:00-13:30	Rune Enger (UiO, Norway)	The glymphatic system, glia, and AD
13:30-14:00	Beatriz Escobar Doncel (Ahus/UiO, Norway)	NAD+ and REST in AD (tentative)
14:00-14:30	Leiv Otto Watne (Ahus/UiO, Norway)	Acute Brain Failure to Chronic Decline: Mechanisms Linking Delirium and Dementia (confirmed)
14:30-15:00	Hua HU	Metabolic efficiency of axonal signalling and its implication in brain diseases.
15:00-15:30	Break	
Chair: Rune Enger (UiO, Norway)		
15:30-16:00	Anne Brita Knapskog (OUS, Norway)	An introduction to the dementia registry NorCog in Norway
16:00-16:30	Jia-Wei Xin (Fu-Jian Medical U., China)	AD diagnosis and treatment in China (tentative)
16:30-17:00	Liu Shi (Nxera Pharma UK, UK)	AD biomarkers and related drug development
17:00-17:30	Harald Hrubos-Strøm (UiO, Norway)	Good sleep to alleviate dementia (tentative)
19:30-22:00	Dinner (invitation only) – Restaurant: to be updated Address: to be updated OPTIONAL -After dinner: Beer in Fridtjof Pub (Address: Fridtjof Nansens plass 7, 0160 Oslo)	Free of one glass of beer /speakers + staff (sponsored by NO-Age AS) Through Prof. Hilde Nilsen

Organizers of the NO-Age/AD meetings

Evandro F. Fang
UiO/Ahus, Norway

Dr. Evandro Fei Fang is a molecular gerontologist whose research focuses on understanding the molecular mechanisms of human ageing and age-related diseases. His team uses bench-top knowledge to guide the development of novel interventional strategies towards human ageing, with a final goal of improving the quality of life in all older people. After finishing his PhD at the Chinese Universtiy of Hong Kong, he completed a 6-year postdoc with Prof. Vilhelm Bohr on molecular gerontology and Prof. Mark Mattson on neuronal resilience in Alzheimer's disease at the National Institute on Ageing, Baltimore; he opened his lab in Oslo in the fall of 2017. He is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing network (NO-Age, www.noage100.com), the Norwegian National anti-Alzheimer's disease Network (NO-AD, www.noad100.com), and the Hong Kong-Nordic Research Network.

Jon Storm-Mathisen
UiO, Norway

"A Father of neurotransmitters", Prof. Jon Storm-Mathisen is a Norwegian brain researcher and is professor emeritus of medicine at the University of Oslo. Retiring officially in 2011, Storm-Mathisen was previously deputy head of the Center for Molecular Biology and Neuroscience. He received the Anders Jahres medical prize in 2006 for his pioneering research on signaling substances in the brain. He received UiO's research prize in 2004. He was also awarded the Nansen Medal and the Lundbeck Prize, and elected member of the Norwegian Academy of Science and Letters. He chaired the inaugural Kavli Prize Committee for Neuroscience.

Linda H. Bergersen
UiO, Norway

The research group of Dr. Linda Bergersen investigates the role of lactate in pathogenic brain as we age. Dr. Bergersen obtained her PhD from the University of Oslo, and she is now a professor at the University of Oslo, holding multiple roles, including Head of Electron Microscopy Laboratory and Leader of the Brain and Muscle Energy Group, Institute of Oral Biology (IOB), Department of Oral Biology (UiO), Professor in Physiology at the Faculty of Dentistry (UiO), and Professor of Neurobiology of Aging at the Center of Healthy Aging (CEHA), University of Copenhagen, Denmark.

Hilde Nilsen
UiO, Norway

Hilde Loge Nilsen is a researcher and professor at the University of Oslo. Her work focuses on studying DNA and RNA quality control mechanisms in human disease, particularly in relation to cancer, aging, and neurodegenerative disorders. With extensive experience and notable contributions in the field, Nilsen investigates the role of DNA repair enzymes and their impact on preventing mutations and maintaining cellular function. Her research also highlights the involvement of DNA repair proteins in RNA quality control. Nilsen's work aims to advance our understanding of tumorigenesis, age-related diseases, and the intricate interplay between DNA and RNA maintenance.

A. Kobro-Flatmoen
NTNU, Norway

I hold a PhD in Neuroscience on the topic of Alzheimer's disease cell-specific vulnerability, from the Kavli Institute for Systems Neuroscience. I now work as a researcher and co-leader of the K.G. Jebsen Center for Alzheimer's Disease (NTNU). I am interested in brain function and malfunction and have a particular interest in neurodegeneration. My main focus concerns the how and why Alzheimer's disease develops, a disease known to heavily target the medial temporal lobe memory system and in particular the entorhinal cortex. I use animal models and cell culture models to address key questions related to the aetiology of dementia. In addition, I work with human brain tissue such that I can relate findings made in models back to the human brain.

Speakers

Xiao-Chun CHEN
Fu-Jian M.U., China

Dr. Xiaochun Chen is a Distinguished Zonglian Scholar Professor, Director of the Institute of Neuroscience at Fujian Medical University, and Chief Physician in Neurology at its Affiliated Union Hospital. He holds leadership roles in national neurology and dementia societies and is Deputy Editor-in-Chief of the Chinese Journal of Neurology. Dr. Chen focuses on clinical and translational research in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, exploring their disease mechanisms and preventive/therapeutic strategies. He has led 20+ nationally funded projects, including the Science and Technology Innovation 2030 - "Brain Science and Brain-Inspired Research" program and key projects funded by the National Natural Science Foundation of China (NSFC). He has published 120+ papers in journals such as Immunity, Neuron. His research has received awards including the Ministry of Education First-Class Natural Science Award.

Zao HAN
SMIDF, China

Mr. Zao Han is the Project Director, responsible for the international collaborations in Shanghai Medical Innovation & Development Foundation. Mr. Han has been in the medical field ever since receiving his master in public policies from University of Chicago, deeply involved in different healthcare innovation technology companies. He is now leading a healthcare data innovative solution company providing data management and AI development services in the fields of neurology, psychiatry and pediatrics. Throughout his professional career he has also established a strong network with policy researchers, clinicians, industry stakeholders as well as academic institutions.



Fei-Xiong CHENG
Cleveland Clinic, USA

The primary goal of Cheng lab (Alzheimer’s Network Medicine Laboratory) is to create and combine research tools to answer the challenging questions surrounding Alzheimer’s diseases (AD) and Alzheimer’s disease-related dementia (ADRD). We develop experimental and computational methods and tools to be applicable to human disease as a whole to maximize the impact they have in identifying features that can be used to better diagnose or treat patients in a personalized manner.

Johannes Frank
Ahus, Norway

Mr. Johannes Frank was an exchange student at the Fang lab for his bachelor’s degree at the University of Applied Sciences in Krems, Austria. After his master’s degree in Molecular Biology with a major in Neuroscience at the University of Vienna, Austria, he joined the Fang lab again as a DPhil student working on ferroptosis and AD. He has published several papers, including in Mechanisms of Ageing and Development and Ageing Research Reviews.



Yong SHEN
USTC, China

Dr. Shen obtained his bachelor degree in biology from Nanjing University and his master degree from the Chinese Academy of Sciences, Shanghai Institute for Physiology, and PhD in Neuroscience from New York State University. Dr. Shen worked for Abbott Pharmaceuticals from 1993-1997, involving in drug develoment for Alzheimer’s disease. From 1997-2010, he worked in Sun Health Research Institute, during which his group developed neuronal culture using brain tissue from aged and Alzheimer’s disease subjects, including neuronal stem cells. Dr. Shen also first show elevation of BACE1 activity in the brain and cerebrospinal fluid in Alzheimer patients. In 2010, he joined the Roskamp Institute as a senior scientist and professor of neuropathology, leading a group dedicated to understand the pathogenic mechanism, identify biomarkers and develop novel therapies for neurodegenrative diseases including AD, PD and vascular dementia.

Jin-Tai YU
Fu-Dan U.,China

Dr. Yu is the Deputy Head of Department of Neurology in Huashan Hospital and the Vice Director of the Institute of Neurology, WHO Collaborating Center for Research and Training in Neurosciences, Fudan University, Shanghai, China. He also directs the Memory Disorders Subspecialty, National Center for Neurological Disorders in China, Huashan Hospital. Currently, he is focusing on basic and clinical research for Alzheimer's disease and related dementia, and the PI of several national grants on dementia, including Science and Technology Innovation 2030 Major Projects and National Natural Science Foundation of China. He has published more than 100 research papers in Nature Human Behaviour, Nature Aging, Lancet Neurology, Science Advances, Alzheimer's & Dementia, et al. that have been cited more than 20000 times by peer scientists in the field. He is currently the Editor-in-Chief of Brain Disorders, Associate Editor-in-Chief of Annals of Translational Medicine, Senior Editor of Journal of Alzheimer's Disease.

Per Selnes
Ahus, Norway

Per Selnes is a neurologist and senior research fellow specializing in neurodegenerative diseases, with a particular focus on early pathophysiological mechanisms underlying biomarker abnormalities. His work integrates advanced MRI, CSF and blood biomarkers, and genetic analyses to study disease onset and progression in Alzheimer's disease and related disorders. A central theme of his recent research is impaired protein clearance, investigated through the study of a rare maternally inherited mitochondrial disorder characterized by reduced CSF production, choroid plexus dysfunction, and disrupted glymphatic clearance in vivo. This human model has provided unique insights into how mitochondrial dysfunction can reshape CSF dynamics and biomarker profiles independently of overt neurodegeneration. His work emphasizes system-level physiology and the interpretation of biomarkers in the context of clearance and transport, with implications for ageing, sleep, and neurodegenerative disease mechanisms.



Guojun Bu
HKUST, Hong Kong

Dr. Guojun Bu is the Lo Ka Chung Charitable Foundation Professor of Science, Head and a Chair Professor in the Division of Life Science at the Hong Kong University of Science and Technology. His prior roles include Chair of the Department of Neuroscience at the Mayo Clinic and Professor of Cell Biology at Washington University in St. Louis. Dr. Bu is a distinguished leader in Alzheimer's disease research, particularly known for his work on APOE and APOE receptors. He has published over 380 articles with more than 54,000 citations and an H-Index of 129. Dr. Bu is an elected Fellow of the American Association for the Advancement of Science and the recipient of numerous honors, including the MetLife Foundation Award for Medical Research. He serves as Editor-in-Chief of Molecular Neurodegeneration, an Associate Editor for Science Advances, and is on the editorial board for Neuron.

Rune Enger
UiO, Norway

Professor of Neuroscience, Division of Anatomy, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo. My research interests are mainly focussed on astrocyte–neuron interplay in the healthy and dysfunctioning brain. See: https://www.med.uio.no/imb/english/research/groups/glial-cells/

Beatriz Escobar-Doncel
Ahus, Norway

Beatriz got her bachelor degree in "Health Biology" at the University of Alcalá (UAH), and her MSc in "Therapeutic Targets in Cell Signaling: Research and Development" both in Spain. She is now doing a PhD in the Fang lab on mechanisms of ageing and Alzheimer's disease, and is actively involved in the development of drug candidates against Alzheimer's disease and in prompting healthy ageing. She has published several papers, including in Brain (in press), Science Advances, and Ageing Research Reviews.

Leiv Otto Watne
Ahus, UiO, Norway

Professor Leiv Otto Watne is a geriatrician at the Department of Geriatric Medicine, Akershus University Hospital, Norway. He is the President of the European Delirium Association and the leader of Oslo Delirium Research Group. The group has carried out pharmacological and non-pharmacological intervention studies, as well as studies on delirium pathophysiology and epidemiology. The group has comprehensive experience in sampling biological and clinical data from patient cohorts. Their biobank of CSF and blood samples from delirious patients is a valuable source of information on pathophysiological mechanisms in delirium.

Hua HU
UiO, Norway

Hua Hu is an associate professor at the Department of Molecular Medicine, University of Oslo. He studies synaptic communication inside healthy and diseased brains with electrophysiological and optical imaging methods.

Anne Brita Knapskog
OUS, Norway

Anne-Brita Knapskog is a geriatrician at Oslo University Hospital and a professor at the faculty of Medicine at the University of Oslo. She leads the Oslo Clinical Dementia Research Group at Oslo University Hospital. The group takes a broad approach to dementia research, with a major emphasis on translational research. In addition, she is affiliated with the K.G. Jebsen Centre for Brain Fluid Research working on the project “Implication of CSF clearance in cognitive impairment” conducted at the Memory Clinic at Oslo University Hospital.

Jia-Wei Xin
Fu-Jian M. U.,China

Dr. Jiawei Xin is an Associate Professor and Associate Chief Physician in the Department of Neurology at the Affiliated Union Hospital of Fujian Medical University, and a graduate supervisor (Master’s students). She serves as the Secretary of the Dementia and Cognitive Disorders Group of the Chinese Medical Association, and holds committee roles in national neurology and geriatrics societies. Dr. Xin has published research articles in journals including Brain, Alzheimer's & Dementia, and BMC Medicine. As a principal investigator, she has led three grants from the National Natural Science Foundation of China (NSFC) a subproject of the National Key R&D Program, and multiple grants from the Fujian Provincial Natural Science Foundation. Her clinical work primarily focuses on cognitive disorders (e.g., memory decline) and associated sleep problems such as insomnia.



Shi Liu
Nxera Pharma UK

Dr. Liu Shi is Associate Director of Bioinformatics and Biomarkers at Nxera Pharma UK, with over 10 years of experience in biomarker discovery and drug development. She has led cross-functional projects across academia and industry, including key roles at Novo Nordisk and the University of Oxford. Her work integrates omics data, machine learning, and translational research to identify novel targets and biomarkers, particularly in neurodegenerative diseases.

Harald Hrubos-Strøm
Ahus and UiO, Norway

Dr. Hrubos-Strøm is the leader of the otorhinoloaryngology research group at Akershus University Hospital and member of the research group "Psychosomatic Aspects of Somatic disease" at the department of Behavioural Sciences. He is the leader of the Akershus Sleep Apnea Epidemiological- and Clinical Cohorts and national co-ordinator of the following on-going projects:

1. Obstruktiv søvnapné - persontilpasset medisin - Akershus universitetssykehus (ahus.no) (Finance Nord Forsk)
2. Søvnapné - teknologisk behandlingsstudie - Akershus universitetssykehus (ahus.no) (Finance: Horizon 2020)
3. Project Hypnos (Finance Eurostars)

Acknowledgements

The NO-Age and NO-AD Seminar Series

U. of Oslo

U. of Copenhagen

Chinese U. of Hong Kong

Norwegian U. of Science and Technology

K.G. Jebsen Centre for Alzheimer's Disease

Kavli Institute for Systems Neuroscience

NO-Age

NO-AD

MIT-AD

Oriel College
University of Oxford

OsloLifeScience
UiO : University of Oslo

npj | aging

S.M.I.D.F
上海医学创新发展基金会
Shanghai Medical Innovation & Development Foundation

The Journals of GERONTOLOGY® SERIES a



Aging and Health RESEARCH

Nasjonalforeningen for folkehelsen

NAS

From the Oslo airport to Thon Cecil (or Thon Bristol)

6:00 AM - 6:37 AM
(37 min)

FLY1 R12 RE10 RE11 >

6:03 AM from Oslo lufthavn stasjon
10 min every 5 min

Add to Calendar

6:00 AM **Oslo Airport**
Edvard Munchs veg, 2061 Gardermoen

Walk
About 3 min, 210 m

6:03 AM **Oslo lufthavn stasjon**

RE10 Drammen
27 min (3 stops) · Platform 4

6:30 AM **Nationaltheatret stasjon**

Walk
About 7 min, 550 m

6:37 AM **Thon Hotel Cecil**
Stortingsgata 8, 0161 Oslo

Tickets and information
Vy - 61 05 19 10

You can take either the Express train (FLYTOGET) or the normal train (VY company) to the direction of ‘Oslo S’, then drop at ‘National Theatre’ (Nationaltheatret stasjon)

Buy the tickets yourself, then get reimbursed

FLYTOGET
AIRPORT EXPRESS

VY



From hotel to meeting room

depart at 9/14/23 07:20

07:20 - 07:41 20 min

07:25 from Stortinget

07:20 **Thon Hotel Cecil, Stortingsgata 8, 0161 Oslo**

Walk
270 m (4 minutes)

07:25 **Stortinget**
(Platform 2)

5 towards Ringen via Majorstuen

- Delays
  There are currently delays on several departures.
  Ruter
- Not serving Stortinget
  Due to post-fire work near Grensen, Stortinget stop will be out of service until further notice. Applies in both directions.
  Ruter
- delays
  Several departures are unfortunately delayed up to approx. 15 minutes due to an unwanted incident on board a train.
  Ruter
- The metro does not stop at Nationaltheatret
  The metro does not stop at Nationaltheatret until further notice. This is due to a fire alarm.
  Ruter

07:33 **Forskningsparken**

Walk
500 m (8 minutes)

07:41 **Domus Medica tilbygg, Gaustadalléen 34, 0373 Oslo**

Meeting room: Domus Medica, Auditorium L-200



Fang lab colleagues (see below) will be meeting you at 7:10 in the Thon Cecil hotel and the Thon Bristol hotel (4 min walking distance) to escort you to the meeting room.

We will provide you bus tickets.

As **the meeting will be started at 8 am in sharp**, we do hope we all could keep in time. Thank you very much.

Shu-qin Cao
UiO, Norway

Beatriz Escobar Doncel
Ahus, Norway

Johannes Frank
Ahus, Norway

To install the software Ruter for public transportation

1.Foreign bank is allowed to link to your Ruter software
2. Oslo city is in zone #1 (once purchased, it lasts for 1 h)
3. Do not forget to buy tickets before to use the public transportation, as one pay get a penalty of 1000 NOK if no valid ticket(s).
4. you can also buy a one-day ticket if you expect more travels.

Ruter#